BRPI0922350A2 - anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. - Google Patents

anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.

Info

Publication number: BRPI0922350A2
Authority: BR; Brazil
Prior art keywords: tissue factor; antibody; sample; detect; bispecific molecule
Prior art date: 2008-12-09

Application number

BRPI0922350A

Other languages

English (en)

Inventor

David P E Satijin

Eva Ehrnrooth

Jan Van De Winkel

Maroeska Oudshoorn

Mischa Houtkamp

Ole Baadsgaard

Paul Parren

Rene M A Hoet

Rob N De Jong

Sandra Verploegen

Tom Vink

Vibeke Miller Breinholt

Willem Karel Bleeker

Original Assignee

Genmab As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-09

Filing date

2009-12-09

Publication date

2016-01-12

2009-12-09 Application filed by Genmab As filed Critical Genmab As

2016-01-12 Publication of BRPI0922350A2 publication Critical patent/BRPI0922350A2/pt

2021-01-12 Publication of BRPI0922350B1 publication Critical patent/BRPI0922350B1/pt

2021-05-25 Publication of BRPI0922350B8 publication Critical patent/BRPI0922350B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0922350A 2008-12-09 2009-12-09 anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico BRPI0922350B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US20133508P	2008-12-09	2008-12-09
US61/201,335		2008-12-09
DKPA200801744		2008-12-09
DKPA200801744		2008-12-09
PCT/EP2009/066755 WO2010066803A2 (en)	2008-12-09	2009-12-09	Human antibodies aganist tissue factor.

Publications (3)

Publication Number	Publication Date
BRPI0922350A2 true BRPI0922350A2 (pt)	2016-01-12
BRPI0922350B1 BRPI0922350B1 (pt)	2021-01-12
BRPI0922350B8 BRPI0922350B8 (pt)	2021-05-25

Family

ID=59050110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922350A BRPI0922350B8 (pt)	2008-12-09	2009-12-09	anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico

Country Status (21)

Country	Link
US (6)	US9150658B2 (pt)
EP (3)	EP3159358B1 (pt)
JP (6)	JP5860285B2 (pt)
KR (2)	KR101998492B1 (pt)
CN (3)	CN119331096A (pt)
AU (1)	AU2009324412B2 (pt)
BR (1)	BRPI0922350B8 (pt)
CA (2)	CA3017575A1 (pt)
DK (1)	DK2376537T3 (pt)
EA (1)	EA201100923A1 (pt)
ES (1)	ES2604635T3 (pt)
IL (1)	IL212856A (pt)
MX (2)	MX338754B (pt)
NZ (1)	NZ786274A (pt)
PL (1)	PL2376537T3 (pt)
PT (1)	PT2376537T (pt)
SG (1)	SG10201500140VA (pt)
SI (1)	SI2376537T1 (pt)
UA (1)	UA109633C2 (pt)
WO (1)	WO2010066803A2 (pt)
ZA (1)	ZA201103723B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1578397T3 (da)	2002-11-15	2013-03-11	Genmab As	Humane monoklonale antistoffer mod CD25
SG10201610247QA (en) *	2008-12-03	2017-02-27	Genmab As	Antibody variants having modifications in the constant region
UA109633C2 (uk)	2008-12-09	2015-09-25		Антитіло людини проти тканинного фактора
EP3539988A3 (en)	2010-05-27	2019-12-04	Genmab A/S	Monoclonal antibodies against her2
CN111012921A (zh) *	2010-06-15	2020-04-17	根马布股份公司	针对组织因子的人抗体药物缀合物
KR20220082104A (ko) *	2010-11-30	2022-06-16	추가이 세이야쿠 가부시키가이샤	세포상해 유도 치료제
US8722044B2 (en) *	2011-03-15	2014-05-13	Janssen Biotech, Inc.	Human tissue factor antibody and uses thereof
CN103796677B (zh) *	2011-04-20	2019-08-16	健玛保	针对her2和cd3的双特异性抗体
JP6177231B2 (ja) *	2011-04-20	2017-08-09	ゲンマブエー／エス	Ｈｅｒ２に対する二重特異性抗体
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9555109B2 (en) *	2012-01-20	2017-01-31	University Of Cincinnati	Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
EP3632462A1 (en)	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
JP6514103B2 (ja)	2012-07-06	2019-05-15	ゲンマブビー．ブイ．	三重変異を有する二量体タンパク質
KR20210096697A (ko)	2013-01-10	2021-08-05	젠맵 비. 브이	인간 IgG1 Fc 영역 변이체 및 그의 용도
JP2017502983A (ja) *	2013-10-02	2017-01-26	スリテクノロジーズエルティーディー．	不均一な腫瘍を処置するための患者特異的免疫療法
ES2983564T3 (es)	2013-11-21	2024-10-23	Genmab As	Formulación liofilizada de conjugado de anticuerpos y fármaco
WO2016077720A1 (en) *	2014-11-14	2016-05-19	Protein One, Llc	Binding agents and uses thereof
WO2017141243A1 (en)	2016-02-18	2017-08-24	Enlivex Therapeutics Ltd.	Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en)	2015-02-18	2023-03-07	Enlivex Therapeutics R&D Ltd	Early apoptotic cells for use in treating sepsis
US11304976B2 (en)	2015-02-18	2022-04-19	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
WO2016132366A1 (en)	2015-02-18	2016-08-25	Enlivex Therapeutics Ltd.	Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en)	2015-02-18	2021-05-11	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en)	2015-02-18	2022-11-15	Enlivex Therapeutics R&D Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en)	2015-02-18	2022-05-03	Enlivex Therapeutics Ltd	Combination immune therapy and cytokine control therapy for cancer treatment
IL287500B2 (en)	2015-04-21	2023-12-01	Enlivex Therapeutics Rdo Ltd	Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017028823A1 (zh) *	2015-08-20	2017-02-23	复旦大学	靶向于组织因子的抗体、其制备方法和用途
EP3347054B1 (en)	2015-09-11	2021-05-05	Genmab A/S	Dosing regimens for anti-tf-antibody drug-conjugates
CN106938051B (zh)	2016-08-22	2019-10-11	复旦大学	靶向于组织因子的抗体-药物偶联物
EP3502141A4 (en) *	2016-08-22	2020-04-08	Fudan University	TISSUE FACTOR TARGET ANTIBODIES, PREPARATION METHOD AND USE THEREOF
US11021533B2 (en)	2016-11-02	2021-06-01	Vanderbilt University	Human Zika virus antibodies and methods of use therefor
CN110352068A (zh)	2016-12-02	2019-10-18	南加利福尼亚大学	合成的免疫受体及其使用方法
TW201922796A (zh) *	2017-10-30	2019-06-16	國立研究開發法人國立癌症研究中心	可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
MX2020004265A (es) *	2017-11-02	2020-08-03	Genmab As	Conjugados de anticuerpos y farmacos de factor anti-tisular y su uso en el tratamiento del cancer.
MX2020007077A (es)	2018-01-04	2020-10-28	Iconic Therapeutics Inc	Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
UA129351C2 (uk) *	2018-03-07	2025-03-26	Генмаб А/С	Кон'югат антитіла до тканинного фактора з лікарським засобом та його застосування для лікування раку
TWI841554B (zh)	2018-03-21	2024-05-11	丹麥商珍美寶股份有限公司	以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
SG11202009986QA (en)	2018-05-07	2020-11-27	Genmab As	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3099547A1 (en)	2018-05-07	2019-11-14	Reshma Abdulla RANGWALA	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EA202190102A1 (ru) *	2018-08-16	2021-07-29	Генмаб А/С	Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN109840471B (zh) *	2018-12-14	2023-04-14	天津大学	一种基于改进Unet网络模型的可行道路分割方法
EP3898959A4 (en) *	2018-12-21	2023-01-11	Board of Regents, The University of Texas System	Phosphorylated dicer antibody and methods of use thereof
AU2020217012A1 (en) *	2019-02-01	2021-08-19	Novarock Biotherapeutics, Ltd.	Anti-claudin 18 antibodies and methods of use thereof
MX2021010857A (es)	2019-03-11	2021-12-15	Janssen Biotech Inc	Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
WO2020212415A1 (en)	2019-04-17	2020-10-22	Novo Nordisk A/S	Bispecific antibodies
CA3155754A1 (en)	2019-11-07	2021-05-14	Reshma Abdulla RANGWALA	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
KR20230008723A (ko)	2020-04-10	2023-01-16	씨젠 인크.	전하 변이체 링커
MX2022015375A (es)	2020-06-29	2023-01-16	Genmab As	Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
CN116322713A (zh) *	2020-07-10	2023-06-23	伊科尼克治疗公司	使用抗组织因子抗体进行炎性疾病治疗
TW202227495A (zh)	2020-09-11	2022-07-16	美商健生生物科技公司	用於調節β鏈介導之免疫的方法及組成物
WO2022056197A1 (en) *	2020-09-11	2022-03-17	Janssen Biotech, Inc.	Immune targeting molecules and uses thereof
TW202233248A (zh)	2020-11-08	2022-09-01	美商西健公司	組合療法
AU2022238571A1 (en)	2021-03-18	2023-09-14	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
MX2023012364A (es)	2021-04-20	2023-11-01	Seagen Inc	Modulacion de citotoxicidad celular dependiente de anticuerpos.
KR20240015670A (ko)	2021-05-28	2024-02-05	씨젠 인크.	안트라사이클린 항체 접합체
WO2023137399A2 (en) *	2022-01-12	2023-07-20	Iconic Therapeutics Llc	Inflammatory disease treatment using anti-tissue factor antibodies
MX2024011292A (es)	2022-03-17	2024-09-27	Seagen Inc	Conjugados de camptotecina.
EP4518904A1 (en)	2022-05-06	2025-03-12	Genmab A/S	Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024129756A1 (en)	2022-12-13	2024-06-20	Seagen Inc.	Site-specific engineered cysteine antibody drug conjugates
US20250122306A1 (en) *	2023-10-13	2025-04-17	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025090774A1 (en)	2023-10-24	2025-05-01	Seagen Inc.	Chemotherapeutic compounds and methods of use

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US835A (en)		1838-07-12		X i i i x
US6077A (en)		1849-01-30		Improved hinged claw-wrench
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en)	1982-06-24	1989-10-18	NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD	Long-acting composition
US4681581A (en)	1983-12-05	1987-07-21	Coates Fredrica V	Adjustable size diaper and folding method therefor
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en)	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5101827A (en)	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US5776093A (en)	1985-07-05	1998-07-07	Immunomedics, Inc.	Method for imaging and treating organs and tissues
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5057313A (en)	1986-02-25	1991-10-15	The Center For Molecular Medicine And Immunology	Diagnostic and therapeutic antibody conjugates
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5437864A (en)	1987-03-31	1995-08-01	The Scripps Research Institute	Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en)	1987-03-31	1993-06-29	The Scripps Research Institute	Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
US5648471A (en)	1987-12-03	1997-07-15	Centocor, Inc.	One vial method for labeling antibodies with Technetium-99m
DE68919361T2 (de)	1988-06-21	1995-05-24	Genentech Inc	Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da)	1989-08-09	1999-07-19	Rhomed Inc	Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
DE69031172T2 (de)	1989-12-22	1998-03-12	Applied Research Systems Ars Holding N.V., Curacao	Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1994025585A1 (en)	1993-04-26	1994-11-10	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5194594A (en)	1990-09-07	1993-03-16	Techniclone, Inc.	Modified antibodies
JP3149960B2 (ja)	1991-01-24	2001-03-26	財団法人化学及血清療法研究所	ヒト組織因子を定量する方法
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
CA2113113A1 (en)	1991-07-08	1993-01-21	Simon W. Kantor	Thermotropic liquid crystal segmented block copolymer
US6063630A (en)	1991-11-05	2000-05-16	Transkaryotic Therapies, Inc.	Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
JPH05244988A (ja)	1992-03-04	1993-09-24	Green Cross Corp:The	抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
AU5093593A (en)	1992-08-28	1994-03-29	Scripps Research Institute, The	Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5879677A (en)	1992-12-09	1999-03-09	The Scripps Research Institute	Method for inhibition of cerebral tissue factor mediated reperfusion damage
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
DK0804070T3 (da)	1993-03-09	2000-08-07	Genzyme Corp	Fremgangsmåde til isolering af proteiner fra mælk
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6077835A (en)	1994-03-23	2000-06-20	Case Western Reserve University	Delivery of compacted nucleic acid to cells
US5879687A (en)	1994-04-22	1999-03-09	Corixa Corporation	Methods for enhancement of protective immune responses
NZ288883A (en)	1994-07-11	1998-12-23	Univ Texas	Conjugates comprising coagulation factors
US5663149A (en)	1994-12-13	1997-09-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5703057A (en)	1995-04-07	1997-12-30	Board Of Regents The University Of Texas System	Expression library immunization
PT833911E (pt)	1995-06-07	2004-09-30	Ortho Mcneil Pharm Inc	Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
KR970029803A (ko)	1995-11-03	1997-06-26	김광호	반도체 메모리장치의 프리차지 회로
JPH09302000A (ja)	1996-05-16	1997-11-25	Chemo Sero Therapeut Res Inst	抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
US6593291B1 (en)	1997-02-06	2003-07-15	Entremed, Inc.	Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5986065A (en) *	1997-03-10	1999-11-16	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US20040229282A1 (en)	1997-03-10	2004-11-18	Sunol Molecular Corporation	Antibodies for inhibiting blood coagulation and methods of use thereof
US6719977B1 (en)	1998-02-12	2004-04-13	The General Hospital Corporation	Methods to potentiate cancer therapies
EP1068296B1 (en)	1998-03-31	2011-08-10	Geron Corporation	Compositions for eliciting an immune response to a telomerase antigen
TR200002885T2 (tr)	1998-04-03	2000-12-21	Chugai Seiyaku Kabushiki Kaisha	İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
EP1108035B1 (en)	1998-09-04	2007-08-08	Sanofi Pasteur Limited	Treatment of cervical cancer
US6387888B1 (en)	1998-09-30	2002-05-14	American Foundation For Biological Research, Inc.	Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
AU2753100A (en)	1999-02-03	2000-08-25	Biosante Pharmaceuticals, Inc.	Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en)	1999-05-14	2001-08-28	Copernicus Therapeutics, Inc.	Automated nucleic acid compaction device
ATE384744T1 (de)	1999-07-29	2008-02-15	Medarex Inc	Menschliche antikörper gegen her2/neu
DE60033530T2 (de)	1999-08-24	2007-10-31	Medarex Inc.	Humane antikörper gegen ctla-4 und deren verwendungen
JP2001213804A (ja)	2000-01-31	2001-08-07	Chugai Pharmaceut Co Ltd	抗組織因子抗体の複合体
AU2001250814B2 (en)	2000-03-16	2007-02-15	Genentech, Inc.	Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2002235141A1 (en)	2000-11-27	2002-06-03	Geron Corporation	Glycosyltransferase vectors for treating cancer
US20040018194A1 (en)	2000-11-28	2004-01-29	Francisco Joseph A.	Recombinant anti-CD30 antibodies and uses thereof
CN1487996B (zh)	2000-11-30	2010-06-16	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
EP1374896A4 (en)	2001-03-26	2005-04-06	Koji Suzuki	MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
US7247304B2 (en)	2001-08-23	2007-07-24	Genmab A/S	Methods of treating using anti-IL-15 antibodies
ES2375271T3 (es)	2001-08-23	2012-02-28	Genmab A/S	Anticuerpos humanos espec�?ficos para interleuquina 15 (il-15).
ATE434404T1 (de)	2001-08-30	2009-07-15	Sinai School Medicine	Alternativ gesplicter zirkulierender gewebefaktor
US20050169927A1 (en) *	2001-10-02	2005-08-04	Novo Nordisk A/S	Human tissue factor antibodies
IL160998A0 (en) *	2001-10-02	2004-08-31	Novo Nordisk As	Human tissue factor antibodies
TWI338009B (en)	2001-10-29	2011-03-01	Genentech Inc	Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003037361A2 (en)	2001-11-02	2003-05-08	Novo Nordisk Health Care Ag	Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20050255111A1 (en)	2002-02-22	2005-11-17	Olle Korsgren	Use of an inhibitor or antagonist against tissue factor
KR101013697B1 (ko)	2002-05-01	2011-02-10	바이엘 쉐링 파마 악티엔게젤샤프트	항응고제로서의 조직 인자 표적화된 신규 트롬보모둘린융합 단백질
AU2003242506A1 (en)	2002-07-12	2004-02-02	Novo Nordisk A/S	Tf antagonist
EP2353611B1 (en)	2002-07-31	2015-05-13	Seattle Genetics, Inc.	Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003277832A1 (en) *	2002-10-31	2004-05-25	Novo Nordisk A/S	Humanized tissue factor antibodies
AU2003275948A1 (en)	2002-11-06	2004-06-07	Novo Nordisk A/S	Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
WO2004041302A1 (en)	2002-11-06	2004-05-21	Novo Nordisk A/S	Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
DK1578397T3 (da)	2002-11-15	2013-03-11	Genmab As	Humane monoklonale antistoffer mod CD25
EP1590364B1 (en)	2002-12-16	2011-10-05	Genmab A/S	Human monoclonal antibodies against interleukin 8 (il-8)
WO2004064870A2 (en)	2003-01-22	2004-08-05	Novo Nordisk A/S	Radiolabelled tissue factor binding agent and the use thereof
US20060034846A1 (en)	2003-04-14	2006-02-16	Mirella Ezban	Use of TF antagonists
US7425328B2 (en)	2003-04-22	2008-09-16	Purdue Pharma L.P.	Tissue factor antibodies and uses thereof
JP2006526641A (ja)	2003-05-30	2006-11-24	セントカー・インコーポレーテツド	抗−組織因子抗体を用いる腫瘍成長を抑制する方法
EP1629014A2 (en)	2003-05-30	2006-03-01	Genentech, Inc.	Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7605235B2 (en)	2003-05-30	2009-10-20	Centocor, Inc.	Anti-tissue factor antibodies and compositions
ES2527102T3 (es)	2003-06-19	2015-01-20	Genentech, Inc.	Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
WO2005025623A2 (en)	2003-07-28	2005-03-24	Emory University	Ef-24-factor vii conjugates
JP2007504167A (ja)	2003-08-29	2007-03-01	セントカー・インコーポレーテツド	抗組織因子抗体を用いる移植片の生存を向上する方法
DK1725249T3 (en)	2003-11-06	2014-03-17	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugating to ligands.
SI1691837T1 (sl)	2003-12-10	2012-11-30	Medarex Inc	Ip protitelesa in njihova uporaba
WO2005079766A2 (en)	2004-02-20	2005-09-01	Novo Nordisk A/S	Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
EP1810979B1 (en)	2004-09-22	2012-06-20	Kyowa Hakko Kirin Co., Ltd.	STABILIZED HUMAN IgG4 ANTIBODIES
EP1676574A3 (en)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Methods for promoting survival of transplanted tissues and cells
EP1945264A2 (en)	2005-10-21	2008-07-23	Genentech, Inc.	Treatment for antiphospholipid-syndrome-related pregnancy complications
ZA200804082B (en) *	2005-11-07	2010-02-24	Scripps Research Inst	Compositions and methods for controlling tissue factor signaling specificity
JP5525729B2 (ja)	2005-11-28	2014-06-18	ゲンマブエー／エス	組換え一価抗体およびその作製方法
WO2008030260A2 (en)	2005-12-22	2008-03-13	Genentech, Inc.	Treatment of variola viral infections using a tissue factor inhibitor
CA2685698A1 (en)	2007-04-30	2008-11-13	Centocor Ortho Biotech Inc.	Anti-tissue factor antibodies and compositions with enhanced effector function
UA109633C2 (uk)	2008-12-09	2015-09-25		Антитіло людини проти тканинного фактора
CN111012921A (zh)	2010-06-15	2020-04-17	根马布股份公司	针对组织因子的人抗体药物缀合物

2009
- 2009-09-12 UA UAA201108545A patent/UA109633C2/ru unknown
- 2009-12-09 SI SI200931566A patent/SI2376537T1/sl unknown
- 2009-12-09 CN CN202210527720.8A patent/CN119331096A/zh active Pending
- 2009-12-09 EP EP16185529.1A patent/EP3159358B1/en active Active
- 2009-12-09 DK DK09801426.9T patent/DK2376537T3/en active
- 2009-12-09 JP JP2011540083A patent/JP5860285B2/ja active Active
- 2009-12-09 CN CN200980156348.7A patent/CN102317319B/zh active Active
- 2009-12-09 MX MX2011005669A patent/MX338754B/es active IP Right Grant
- 2009-12-09 EA EA201100923A patent/EA201100923A1/ru unknown
- 2009-12-09 KR KR1020177012653A patent/KR101998492B1/ko active Active
- 2009-12-09 US US13/133,811 patent/US9150658B2/en active Active
- 2009-12-09 BR BRPI0922350A patent/BRPI0922350B8/pt active IP Right Grant
- 2009-12-09 AU AU2009324412A patent/AU2009324412B2/en active Active
- 2009-12-09 CA CA3017575A patent/CA3017575A1/en active Pending
- 2009-12-09 PL PL09801426T patent/PL2376537T3/pl unknown
- 2009-12-09 CA CA2746101A patent/CA2746101C/en active Active
- 2009-12-09 PT PT98014269T patent/PT2376537T/pt unknown
- 2009-12-09 CN CN201610367892.8A patent/CN106632678B/zh active Active
- 2009-12-09 WO PCT/EP2009/066755 patent/WO2010066803A2/en active Application Filing
- 2009-12-09 NZ NZ786274A patent/NZ786274A/en unknown
- 2009-12-09 ES ES09801426.9T patent/ES2604635T3/es active Active
- 2009-12-09 KR KR1020117015836A patent/KR101736447B1/ko active Active
- 2009-12-09 EP EP09801426.9A patent/EP2376537B1/en active Active
- 2009-12-09 SG SG10201500140VA patent/SG10201500140VA/en unknown
- 2009-12-09 EP EP23202086.7A patent/EP4279140A3/en active Pending
2011
- 2011-05-12 IL IL212856A patent/IL212856A/en active IP Right Grant
- 2011-05-20 ZA ZA2011/03723A patent/ZA201103723B/en unknown
- 2011-05-27 MX MX2016005494A patent/MX355181B/es unknown
2015
- 2015-08-28 US US14/839,514 patent/US9714297B2/en active Active
- 2015-12-18 JP JP2015246927A patent/JP6236056B2/ja active Active
2017
- 2017-06-19 US US15/626,866 patent/US20180044431A1/en not_active Abandoned
- 2017-10-27 JP JP2017207768A patent/JP6592491B2/ja active Active
2018
- 2018-08-16 US US15/998,816 patent/US20190169311A1/en not_active Abandoned
2019
- 2019-09-20 JP JP2019171368A patent/JP7069095B2/ja active Active
2020
- 2020-05-21 US US16/880,241 patent/US20210171657A1/en not_active Abandoned
2022
- 2022-01-28 JP JP2022011455A patent/JP2022078018A/ja active Pending
- 2022-12-06 US US18/062,473 patent/US20230416403A1/en active Pending
2023
- 2023-10-31 JP JP2023186212A patent/JP2024001285A/ja active Pending

Also Published As

Publication number	Publication date
EA201100923A1 (ru)	2011-12-30
US20230416403A1 (en)	2023-12-28
MX2011005669A (es)	2011-06-17
EP2376537A2 (en)	2011-10-19
EP4279140A3 (en)	2024-01-31
JP2022078018A (ja)	2022-05-24
EP3159358A1 (en)	2017-04-26
AU2009324412B2 (en)	2016-04-21
CN106632678A (zh)	2017-05-10
JP5860285B2 (ja)	2016-02-16
EP2376537B1 (en)	2016-09-28
US20180044431A1 (en)	2018-02-15
WO2010066803A3 (en)	2010-08-19
JP7069095B2 (ja)	2022-05-17
KR101998492B1 (ko)	2019-07-09
CN102317319A (zh)	2012-01-11
CA2746101A1 (en)	2010-06-17
JP2020022461A (ja)	2020-02-13
US20160053020A1 (en)	2016-02-25
KR20110104944A (ko)	2011-09-23
SI2376537T1 (sl)	2017-02-28
US20110300156A1 (en)	2011-12-08
MX355181B (es)	2018-04-09
PL2376537T3 (pl)	2017-06-30
JP2024001285A (ja)	2024-01-09
JP2018038418A (ja)	2018-03-15
US20210171657A1 (en)	2021-06-10
US9150658B2 (en)	2015-10-06
ES2604635T3 (es)	2017-03-08
BRPI0922350B8 (pt)	2021-05-25
MX338754B (es)	2016-04-29
DK2376537T3 (en)	2017-01-23
PT2376537T (pt)	2016-12-26
US20190169311A1 (en)	2019-06-06
CN102317319B (zh)	2016-06-29
IL212856A (en)	2016-09-29
KR101736447B1 (ko)	2017-05-16
CA3017575A1 (en)	2010-06-17
NZ786274A (en)	2023-09-29
JP2012511314A (ja)	2012-05-24
SG10201500140VA (en)	2015-03-30
UA109633C2 (uk)	2015-09-25
US9714297B2 (en)	2017-07-25
CA2746101C (en)	2018-10-30
CN119331096A (zh)	2025-01-21
KR20170056025A (ko)	2017-05-22
JP6236056B2 (ja)	2017-11-22
EP4279140A2 (en)	2023-11-22
JP6592491B2 (ja)	2019-10-16
JP2016138089A (ja)	2016-08-04
WO2010066803A2 (en)	2010-06-17
ZA201103723B (en)	2012-09-26
BRPI0922350B1 (pt)	2021-01-12
EP3159358B1 (en)	2023-10-11
CN106632678B (zh)	2022-05-31
AU2009324412A1 (en)	2011-06-30
IL212856A0 (en)	2011-07-31

Publication	Publication Date	Title
BRPI0922350A2 (pt)	2016-01-12	anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
ECSP11011297A (es)	2011-10-31	Proteinas ligadoras il-17
UA113712C2 (xx)	2017-02-27	Антитіло до fap і способи його застосування
CL2011000230A1 (es)	2011-06-24	Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BRPI1007321A2 (pt)	2018-07-10	métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
AR088513A1 (es)	2014-06-18	Inmunoenlazantes dirigidos contra esclerostina
BR112014003999A2 (pt)	2017-06-13	anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
BR112012001984B8 (pt)	2021-05-25	anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112013002444A2 (pt)	2016-05-24	anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CL2011002765A1 (es)	2012-07-20	Anticuerpo anti-factor de crecimiento nervioso (ngf) con estabilidad in vivo aumentada; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; kit; y su uso para tratar una enfermedad o afeccion relacionada con ngf.
CL2013000535A1 (es)	2014-03-21	Proteina de enlace que se une especificamente a metaloproteinasa de matriz 9 (mmp9); acido nucleico que la codifica; vector; celula; composicion farmaceutica que lo comprende; su uso para tratar un tumor que tiene actividad mmp9; y metodo in vitro de deteccion de mm9 en un tejido de un paciente.
BR112015017548A8 (pt)	2019-10-29	construção de anticorpo multiespecífico isolado, sequência de ácido nucléico, vetor, célula hospedeira, processo para a produção da construção de anticorpo, composição farmaceutica, uso da construção de anticorpo e kit
ECSP12012272A (es)	2012-11-30	Proteínas que se unen al tnf-?
BR112012030139A2 (pt)	2017-06-13	composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
BR112012012887A2 (pt)	2017-05-02	minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
BR112013014527A2 (pt)	2017-03-07	anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
BR112012008665A2 (pt)	2016-11-22	tratamento de câncer
IT1406051B1 (it)	2014-02-06	Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112016004324A2 (pt)	2017-10-24	anticorpos
BR112012026707A2 (pt)	2017-03-14	uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BR112012016229A2 (pt)	2017-03-07	método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab
CL2009000862A1 (es)	2009-08-14	Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-02-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-08-11	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-11-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-01-12	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-03-29	B22B	Petition not considered [chapter 22.2 patent gazette]	Free format text: NAO CONHECIDA A PETICAO NO 870210067567, DE 26/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI
2024-11-19	B25G	Requested change of headquarter approved	Owner name: GENMAB A/S (DK)
2024-12-03	B25G	Requested change of headquarter approved	Owner name: GENMAB A/S (DK)
2024-12-17	B25G	Requested change of headquarter approved	Owner name: GENMAB A/S (DK)